Dr. Figlin on TKI Therapy Options in Renal Cell Carcinoma

Dr. Figlin on TKI Therapy Options in Renal Cell Carcinoma

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line RCCПодробнее

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line RCC

Dr. Figlin on Promise of Immunotherapy Plus TKI Combinations in RCCПодробнее

Dr. Figlin on Promise of Immunotherapy Plus TKI Combinations in RCC

Dr. Figlin Discusses Sequencing mTOR Inhibitors and TKIs in RCCПодробнее

Dr. Figlin Discusses Sequencing mTOR Inhibitors and TKIs in RCC

Dr. Figlin on Advice for Oncologists Treating RCCПодробнее

Dr. Figlin on Advice for Oncologists Treating RCC

The Role of Tyrosine Kinase Inhibitors and mTOR InhibitorsПодробнее

The Role of Tyrosine Kinase Inhibitors and mTOR Inhibitors